Incidence and outcomes of FGFR inhibitor-associated retinopathy of patients treated with oral erdafitinib across the clinical trial program.
- DOI
- 10.1093/oncolo/oyag174
- Published
- 2026 Jun 6
- Container
- The oncologist
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1093/oncolo/oyag174,
title = {Incidence and outcomes of FGFR inhibitor-associated retinopathy of patients treated with oral erdafitinib across the clinical trial program.},
author = {O'Hagan A and Siefker-Radtke A and Loriot Y and Deprince K and Crow L and Laron M and Adelman R and Sweiti H and Triantos S},
year = {2026},
journal = {The oncologist},
doi = {10.1093/oncolo/oyag174},
url = {https://doi.org/10.1093/oncolo/oyag174}
}RIS
TY - JOUR TI - Incidence and outcomes of FGFR inhibitor-associated retinopathy of patients treated with oral erdafitinib across the clinical trial program. AU - O'Hagan A AU - Siefker-Radtke A AU - Loriot Y AU - Deprince K AU - Crow L AU - Laron M AU - Adelman R AU - Sweiti H AU - Triantos S PY - 2026 JO - The oncologist DO - 10.1093/oncolo/oyag174 UR - https://doi.org/10.1093/oncolo/oyag174 ER -
APA
A, O., A, S., Y, L., K, D., L, C., M, L., R, A., H, S., & S, T. (2026). Incidence and outcomes of FGFR inhibitor-associated retinopathy of patients treated with oral erdafitinib across the clinical trial program.. The oncologist. https://doi.org/10.1093/oncolo/oyag174
Source records
- pubmed · retrieved 2026-09-27T13:33:56.261Z